Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Lipophorin Receptor Gene <i>GdLpR</i> Regulates Reproductive Diapause in <i>Galeruca daurica</i>.

Insects·2026
Same author

Absence of EOGT precludes defective development in fringe-null mouse intestine.

Biochimica et biophysica acta. General subjects·2026
Same author

Chromatin rewiring of β-globin and MYC enhancers by TGF-β1 drives defective erythropoiesis.

Nature communications·2026
Same author

Expression Characteristics of Gustatory Receptor Genes in <i>Galeruca daurica</i> (Coleoptera: Chrysomelidae) and Adult Behavioral and Electrophysiological Responses to Host Metabolites.

Insects·2026
Same author

Cardiorenal risk stratification in high-risk type 2 diabetes using a simple clinical score: findings from the ELIXA trial.

Frontiers in endocrinology·2026
Same author

Treatment of <i>TP53</i>-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax.

Haematologica·2026

Related Experiment Video

Updated: Jul 15, 2026

Colony Forming Cell (CFC) Assay for Human Hematopoietic Cells
11:30

Colony Forming Cell (CFC) Assay for Human Hematopoietic Cells

Published on: December 18, 2010

Colony-Forming Unit Assay Adapted For Patient-Derived Bone Marrow and Peripheral Blood Mononuclear Cells.

Mariapia Riso1, Prachiben P Patel2, Jinghang Zhang3

  • 1Department of Developmental & Molecular Biology, Albert Einstein College of Medicine; Ruth L. and David S. Gottesman Stem Cell Institute, Albert Einstein College of Medicine; Montefiore-Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine; mariapia.riso@einsteinmed.edu.

Journal of Visualized Experiments : Jove
|July 13, 2026
PubMed
Summary

This study optimizes the colony-forming unit (CFU) assay for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patient samples. The enhanced protocol ensures reliable hematopoietic stem and progenitor cell growth and differentiation for improved hematologic malignancy research.

More Related Videos

Identification and Isolation of Burst-Forming Unit and Colony-Forming Unit Erythroid Progenitors from Mouse Tissue by Flow Cytometry
08:31

Identification and Isolation of Burst-Forming Unit and Colony-Forming Unit Erythroid Progenitors from Mouse Tissue by Flow Cytometry

Published on: November 4, 2022

Related Experiment Videos

Last Updated: Jul 15, 2026

Colony Forming Cell (CFC) Assay for Human Hematopoietic Cells
11:30

Colony Forming Cell (CFC) Assay for Human Hematopoietic Cells

Published on: December 18, 2010

Identification and Isolation of Burst-Forming Unit and Colony-Forming Unit Erythroid Progenitors from Mouse Tissue by Flow Cytometry
08:31

Identification and Isolation of Burst-Forming Unit and Colony-Forming Unit Erythroid Progenitors from Mouse Tissue by Flow Cytometry

Published on: November 4, 2022

Area of Science:

  • Hematology
  • Stem Cell Biology
  • Cancer Research

Background:

  • The colony-forming unit (CFU) assay is crucial for studying hematologic malignancies like myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
  • Patient-derived samples present challenges including low viability, sensitivity to handling, and variable colony growth.
  • Existing CFU assay guidelines lack standardization in colony identification and counting, hindering reproducibility.

Purpose of the Study:

  • To develop and present an optimized protocol for CFU assays using patient-derived MDS and AML samples.
  • To address the technical challenges associated with low-viability and sensitive patient hematopoietic stem and progenitor cells.
  • To establish standardized metrics for consistent colony counting and analysis in hematologic malignancy research.

Main Methods:

  • The protocol emphasizes gentle cell handling and sterile processing of patient peripheral blood and bone marrow specimens.
  • Optimized culture conditions and specific growth durations were determined for patient-derived hematopoietic stem and progenitor cells.
  • Defined cytokine combinations were used to support three-dimensional growth and lineage-specific differentiation.

Main Results:

  • The optimized protocol facilitates the growth and differentiation of hematopoietic stem and progenitor cells from MDS and AML patient samples.
  • The protocol provides a practical framework for performing CFU assays with challenging patient-derived materials.
  • Standardized colony counting and analysis metrics were established for improved reproducibility.

Conclusions:

  • This optimized CFU assay protocol offers a reliable method for studying hematopoietic stem and progenitor cells from MDS and AML patients.
  • The standardized approach enhances the reproducibility and consistency of CFU assays in hematologic malignancy research.
  • The protocol serves as a valuable tool for advancing the understanding and treatment of MDS and AML.